Lilly's tirzepatide lowered the chance of worsening heart failure events by 38% in adults who have HFpEF and obesity.

AbelZeta showcases preliminary findings on C-CAR168 for autoimmune disease treatment at ACR Convergence 2024.

Rona Therapeutics showcased encouraging Phase 1 findings for RN0191, an innovative siRNA treatment aimed at PCSK9, during the 2024 AHA Scientific Sessions.

AbbVie has obtained approval from the European Commission for ELAHERE® (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer.

Biosion has signed a global exclusive licensing deal with Aclaris Therapeutics for two promising immunology products that could be first-in-class and best-in-class.

Capstan Therapeutics showcases preclinical findings on its primary in vivo CAR-T candidate, CPTX2309, during the ACR Convergence 2024 event.

Neurogene has provided an update regarding its ongoing Phase 1/2 open-label clinical study assessing the NGN-401 gene therapy.

Adicet Bio reports the dosing of the initial lupus nephritis patient in its Phase 1 trial of ADI-001 for autoimmune conditions.

Arrowhead Pharmaceuticals has filed a New Drug Application with the U.S. FDA for plozasiran to treat Familial Chylomicronemia Syndrome.

Seismic Therapeutics showcases new preclinical findings for S-4321, a next-gen bifunctional agonist antibody that targets PD-1 and FcγRIIb.

The trial tests TGN-S11 alone and in combination with Keytruda® (pembrolizumab) for stage 4 cancer patients associated with Human Papillomavirus.

Samsung Bioepis and Biogen have obtained approval from the European Commission (EC) for their Aflibercept biosimilar, named OPUVIZ.